Managing acute exacerbations of schizophrenia: Focus on quetiapine

Current Medical Research and Opinion

Volumn 20, Issue 5, 2004, Pages 619-626

  Arango, Celso ^a   Bobes, Julio ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Acute management; Dose; Quetiapine; Schizophrenia; Titration

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGGRESSION; AKATHISIA; ANXIETY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPHORIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HOSTILITY; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; OUTCOMES RESEARCH; PARKINSONISM; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RATING SCALE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; WEIGHT GAIN;

ACUTE DISEASE; ADMINISTRATION, ORAL; ALGORITHMS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 2542490102     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003430     Document Type: Review

References (39)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. www.psych.org [accessed 24 April 2003]
2. Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series: treatment of behavioral emergencies. Postgrad Med 2001:1-88 [Special Report]
3. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002;14:47-57
4. Arvanitis LA, Miller BG, the Seroquel Trial 13 study group. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46
5. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000;30:95-105
6. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000;15:121-31
7. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73
8. Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69
9. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-57
10. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-49
11. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002;63:1156-63
12. Arvanitis LA, Rak IW. The long-term efficacy and safety of 'Seroquel' (quetiapine). Schizophr Res 1997;24:196-7
13. Buckley PF. Maintenance treatment for schizophrenia with quetiapine [in preparation]
14. Kasper S. NR239: maintenance of long-term efficacy and safety of quetiapine in the treatment of schizophrenia. American Psychiatric Association 155th Annual Meeting, New Orleans, Louisiana, USA, 5-10 May 2002
15. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8
16. Allen MH, Carpenter D, Sheets JL, et al. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Prac 2003;9:39-58
17. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale and research. Schizophr Bull 1996;22:201-22
18. Chengappa KNR, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003;25:530-41
19. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia [in preparation]
20. Ganesan S, Levy M, Bilsker D. Effectiveness of quetiapine treatment of aggressive psychosis in the emergency psychiatric setting: a naturalistic pilot study. American Psychiatric Association 156th Annual Meeting, California, San Francisco, USA, 17-22 May 2003
21. AstraZeneca. Seroquel® (quetiapine fumarate) tablets US Prescribing Information. www.Seroquel.com 2003
22. AstraZeneca. Seroquel™ Prescribing Information Core International Data Sheet. www.psychiatry-in-practice.com 2003
23. King DJ, Link CGG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998;137:139-46
24. Chengappa KNR, Parepally H, Brar JS, et al. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 2003;48:187-94
25. Smith MA, McCoy R, Hamer J, Brecher M. Optimal titration for quetiapine: pilot trial. College of Psychiatric and Neurologic Pharmacists 5th Annual Meeting, Seattle, Washington, USA, 18-21 April 2002
26. Bobes J, Garcia-Portilla MP, Saiz PA, et al. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J Clin Psychiatry 2002;63:1048-9
27. De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7:59-66
28. Keks N, Tonso M, Tabone K, et al. Experience with atypical antipsychotics in an acute inpatient unit. International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA, 29 March-2 April 2003
29. Nagy J. Effectiveness of quetiapine up to 1600 mg/day: short-term results with 14-month follow-up. 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, 20-24 September 2003
30. Hellewell JS, Haddad PM. Differing tolerability profiles among atypical antipsychotics. Am J Psychiatry 2001;158:501-2
31. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
32. Olanzapine Prescribing Information. Zyprexa® (olanzapine) tablets. 2003
33. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(Suppl 5):29-35
34. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505
35. Hellewell JSE, Kalali AH, Langham SJ, et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999;3:105-13
36. Bartkó G, Váradi H, Simon L, et al. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiatry Clin Pract 2002;6:9-14
37. Chue P, Abouelnasr W, Escobedo S, et al. A Canadian multicentre patient satisfaction study with oral long-term quetiapine treatment. Canadian Psychiatric Association, Banff, Alberta, Canada, 31 October-3 November 2002
38. Simons WR, Bassi R, White R. Antipsychotic compliance evaluation: a population-based managed care study of persistence with initially prescribed antipsychotic medication. International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress, Cannes, France, 11-13 November 2001
39. Simons WR. Persistency and Compliance Evaluation (PACE): a US population-based analysis of persistency with initially prescribed antipsychotics. College of Psychiatric and Neurologic Pharmacists 6th Annual Meeting, Charleston, South Carolina, USA, 1-4 May 2003